Now showing items 1-11 of 11

    • Anticholinergics for neuroleptic-induced acute akathisia 

      Rathbone, John (2006)
      Background: Neuroleptic-induced akathisia is one of the most common and distressing early-onset adverse effects of first generation 'typical' antipsychotic drugs. It is associated with poor compliance with treatment, and ...
    • Benzodiazepines for psychosis-induced aggression or agitation 

      Rathbone, John (2005)
      Background: Acute psychotic illness, especiallywhen associatedwith agitated or violent behaviour, can require urgent pharmacological tranquillisation or sedation. In several countries, clinicians often use benzodiazepines ...
    • Clotiapine for acute psychotic illnesses 

      Rathbone, John (2004)
      Background: Acute psychotic illnesses, especially when associated with agitated or violent behaviour, require urgent pharmacological tranquillisation or sedation. Clotiapine, a dibenzothiazepine neuroleptic, is being used ...
    • Clozapine versus typical neuroleptic medication for schizophrenia 

      Rathbone, John (2009)
      Background: Long-term drug treatment of schizophrenia with typical antipsychotics has limitations: 25 to 33% of patients have illnesses that are treatment-resistant. Clozapine is an antipsychotic drug, which is claimed to ...
    • Depot perphenazine decanoate and enanthate for schizophrenia 

      Rathbone, John (2005)
      Background: Antipsychotic drugs are usually given orally but compliance with medication given by this route may be difficult to quantify. The development of depot injections in the 1960s gave rise to extensive use of depots ...
    • Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia 

      Rathbone, John (2004)
      Background: Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. Gamma-aminobutyric acid (GABA) agonist drugs, which have intense sedative properties and may exacerbate ...
    • Olanzapine for schizophrenia 

      Rathbone, John (2005)
      Background: Olanzapine is an atypical antipsychotic reported to be effective without producing disabling extrapyramidal adverse effects associated with older, typical antipsychotic drugs. Objectives: To determine the ...
    • Open general medical wards versus specialist psychiatric units for acute psychoses 

      Rathbone, John (2007)
      Background: As international healthcare policy has moved away from treating people with severe mental illness in large inpatient psychiatric institutions, beds for people with acute psychiatric disorders are being established ...
    • Pimozide for schizophrenia or related psychoses 

      Rathbone, John (2007)
      Background: Pimozide, formulated in the 1960s, continues to be marketed for the care of people with schizophrenia or related psychoses such as delusional disorder. It has been associated with cardiotoxicity and sudden ...
    • Thioridazine for schizophrenia 

      Rathbone, John (2007)
      Background: Thioridazine is an antipsychotic that can still be used for schizophrenia although it is associated with the cardiac arrhythmia, torsades de pointe. Objectives: To review the effects of thioridazine for people ...
    • Zotepine for schizophrenia 

      Rathbone, John (2006)
      Background: Zotepine is a relatively new antipsychotic often used for the treatment of people with schizophrenia. It is claimed to be particularly effective for negative symptoms. Objectives: To determine the effects of ...